|
MX2009010611A
(es)
*
|
2007-04-03 |
2010-03-26 |
Micromet Ag |
Enlazadores biespecificos, especificos para especies.
|
|
RS52492B
(sr)
*
|
2007-04-03 |
2013-02-28 |
Amgen Research (Munich) Gmbh |
Molekuli koji se interspecijski specifično bispecifično vezuju
|
|
RU2769948C2
(ru)
*
|
2007-04-03 |
2022-04-11 |
Эмджен Рисерч (Мьюник) Гмбх |
CD3-Эпсилон-связывающий домен с межвидовой специфичностью
|
|
RS53008B2
(sr)
*
|
2007-04-03 |
2022-12-30 |
Amgen Res Munich Gmbh |
Interspecijski specifičan cd3-epsilon vezujući domen
|
|
US20110014117A1
(en)
*
|
2007-06-28 |
2011-01-20 |
Schering Corporation |
Anti-igf1r
|
|
EP2173163A4
(en)
*
|
2007-07-06 |
2010-12-08 |
Glaxosmithkline Llc |
ANTIBODY FORMULATIONS
|
|
WO2009111889A1
(en)
*
|
2008-03-13 |
2009-09-17 |
The Hospital For Sick Children |
Lymphocyte control of obesity and insulin resistance
|
|
EP2352765B1
(en)
|
2008-10-01 |
2018-01-03 |
Amgen Research (Munich) GmbH |
Cross-species-specific single domain bispecific single chain antibody
|
|
EP2370467B1
(en)
*
|
2008-10-01 |
2016-09-07 |
Amgen Research (Munich) GmbH |
Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
|
|
US20110293619A1
(en)
|
2008-10-01 |
2011-12-01 |
Micromet Ag |
CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
|
|
WO2010132872A1
(en)
*
|
2009-05-15 |
2010-11-18 |
Novimmune S.A |
Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
|
|
CA2778334A1
(en)
*
|
2009-10-20 |
2011-04-28 |
Charlotte Mckee |
Anti-cd3 antibody dosing in autoimmune disease
|
|
NZ602685A
(en)
|
2010-03-01 |
2014-10-31 |
Cytodyn Inc |
Concentrated protein formulations and uses thereof
|
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究（慕尼黑）有限責任公司 |
跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
|
|
PT3434767T
(pt)
|
2010-11-30 |
2026-01-23 |
Chugai Pharmaceutical Co Ltd |
Agente terapêutico indutor de citotoxicidade
|
|
WO2012098238A1
(en)
|
2011-01-21 |
2012-07-26 |
Novimmune S.A. |
Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
|
|
US8974782B2
(en)
*
|
2011-02-07 |
2015-03-10 |
Glaxo Group Limited |
Treatment of stroke comprising anti-MAG antibodies
|
|
EP2683735A1
(en)
|
2011-03-10 |
2014-01-15 |
HCO Antibody, Inc. |
Bispecific three-chain antibody-like molecules
|
|
KR102060389B1
(ko)
|
2011-05-21 |
2019-12-31 |
마크로제닉스, 인크. |
사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
|
|
WO2013073968A2
(en)
*
|
2011-09-12 |
2013-05-23 |
Industrial Research Limited |
Agents for modulation of cell signalling
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
|
HUE042040T2
(hu)
|
2012-09-27 |
2019-06-28 |
Merus Nv |
Bispecifikus IGG antitestek mint T-sejt kapcsolók
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR102211837B1
(ko)
*
|
2013-01-14 |
2021-02-03 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
AU2014229282B2
(en)
*
|
2013-03-15 |
2017-02-02 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Low concentration antibody formulations
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
JP6594855B2
(ja)
*
|
2013-03-15 |
2019-10-23 |
ゼンコア インコーポレイテッド |
ヘテロ二量体タンパク質
|
|
EP3415534A1
(en)
*
|
2013-05-10 |
2018-12-19 |
Numab Therapeutics AG |
Bispecific constructs and their use in the treatment of various diseases
|
|
CN105722859B
(zh)
|
2013-07-25 |
2021-05-07 |
西托姆克斯治疗公司 |
多特异性抗体、多特异性可活化抗体及其使用方法
|
|
EP3699195A3
(en)
|
2014-03-28 |
2020-11-04 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
WO2016001810A1
(en)
|
2014-07-01 |
2016-01-07 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
CA2966905A1
(en)
|
2014-11-12 |
2016-05-19 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
PE20171324A1
(es)
|
2014-11-26 |
2017-09-11 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
|
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
US9914777B2
(en)
*
|
2015-07-10 |
2018-03-13 |
Merus N.V. |
Human CD3 binding antibody
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
CA3007030A1
(en)
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
|
JP7010854B2
(ja)
|
2016-06-14 |
2022-01-26 |
ゼンコア インコーポレイテッド |
二重特異性チェックポイント阻害剤抗体
|
|
KR20250175345A
(ko)
|
2016-06-21 |
2025-12-16 |
테네오바이오, 인코포레이티드 |
Cd3 결합 항체
|
|
CN109715663B
(zh)
|
2016-06-28 |
2022-11-25 |
Xencor股份有限公司 |
结合生长抑素受体2的异源二聚抗体
|
|
CN116617387A
(zh)
*
|
2016-08-29 |
2023-08-22 |
迪赞纳生命科学公开有限公司 |
抗cd3抗体制剂
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
PE20241349A1
(es)
|
2016-09-14 |
2024-07-03 |
Teneobio Inc |
Anticuerpos de union a cd3
|
|
MY203000A
(en)
|
2016-10-14 |
2024-06-01 |
Xencor Inc |
Il15/il15r� heterodimeric fc-fusion proteins
|
|
WO2018106945A1
(en)
|
2016-12-07 |
2018-06-14 |
Progenity Inc. |
Gastrointestinal tract detection methods, devices and systems
|
|
IL317134A
(en)
|
2016-12-21 |
2025-01-01 |
Teneobio Inc |
An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
|
|
WO2018183929A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
JP7382232B2
(ja)
|
2017-05-02 |
2023-11-16 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
|
|
AU2018269370B2
(en)
|
2017-05-16 |
2025-06-05 |
The Johns Hopkins University |
Manabodies and methods of using
|
|
EP3634478A4
(en)
*
|
2017-06-06 |
2021-03-24 |
The Brigham and Women's Hospital, Inc. |
METHOD OF SUPPRESSION OF MICROGLIA ACTIVATION
|
|
CN110945026B
(zh)
|
2017-06-20 |
2024-03-19 |
特纳奥尼股份有限公司 |
仅有重链的抗bcma抗体
|
|
KR20250007003A
(ko)
|
2017-06-20 |
2025-01-13 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
|
KR20200068647A
(ko)
|
2017-08-11 |
2020-06-15 |
시티 오브 호프 |
트랜스페린 수용체 (TfR)에 대한 RNA 앱타머
|
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
IL275426B2
(en)
|
2017-12-19 |
2025-03-01 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
JP2021508479A
(ja)
|
2017-12-27 |
2021-03-11 |
テネオバイオ， インコーポレイテッド |
ヘテロ二量体特異的抗体上のｃｄ３デルタ及びｃｄ３イプシロン
|
|
CA3096052A1
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
|
AU2019355971B2
(en)
|
2018-10-03 |
2025-05-08 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
|
CN113166261A
(zh)
|
2018-10-11 |
2021-07-23 |
印希比股份有限公司 |
B7h3单域抗体及其治疗性组合物
|
|
JP7611820B2
(ja)
|
2018-10-11 |
2025-01-10 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
|
|
JP2022504802A
(ja)
|
2018-10-11 |
2022-01-13 |
インヒブルクス インコーポレイテッド |
５ｔ４シングルドメイン抗体およびその治療組成物
|
|
CN120623346A
(zh)
|
2018-10-11 |
2025-09-12 |
因荷布瑞克斯生物科学公司 |
Pd-1单结构域抗体及其治疗组合物
|
|
WO2020081408A1
(en)
|
2018-10-18 |
2020-04-23 |
Merck Sharp & Dohme Corp. |
Formulations of anti-rsv antibodies and methods of use thereof
|
|
MX2021004928A
(es)
|
2018-10-31 |
2021-06-08 |
Merck Sharp & Dohme Llc |
Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
|
|
EP3876990A4
(en)
|
2018-11-07 |
2023-09-06 |
Merck Sharp & Dohme LLC |
CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
|
|
EP3883635A1
(en)
|
2018-11-19 |
2021-09-29 |
Progenity, Inc. |
Methods and devices for treating a disease with biotherapeutics
|
|
KR20210096640A
(ko)
*
|
2018-11-29 |
2021-08-05 |
하버 바이오메드 테라푸틱스 리미티드 |
항-pd-l1 항체 제제
|
|
CA3132185A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
WO2020206330A1
(en)
|
2019-04-05 |
2020-10-08 |
Teneobio, Inc. |
Heavy chain antibodies binding to psma
|
|
WO2020232247A1
(en)
|
2019-05-14 |
2020-11-19 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
|
CR20210622A
(es)
|
2019-06-14 |
2022-06-27 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
|
JP6881658B2
(ja)
|
2019-07-05 |
2021-06-02 |
小野薬品工業株式会社 |
Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
|
|
JP7725466B2
(ja)
|
2019-11-13 |
2025-08-19 |
アムニクス ファーマシューティカルズ， インコーポレイテッド |
バーコード化されたｘｔｅｎポリペプチドおよびその組成物、ならびにその作製および使用方法
|
|
CN115666704B
(zh)
|
2019-12-13 |
2025-09-26 |
比特比德科有限责任公司 |
用于将治疗剂递送至胃肠道的可摄取装置
|
|
IL297601A
(en)
|
2020-04-29 |
2022-12-01 |
Teneobio Inc |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
MX2022013797A
(es)
|
2020-05-08 |
2022-11-30 |
Genmab As |
Anticuerpos biespecificos contra cd3 y cd20.
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
IL298999A
(en)
|
2020-06-11 |
2023-02-01 |
Provention Bio Inc |
Methods and compositions for the prevention of type 1 diabetes
|
|
KR20230041711A
(ko)
|
2020-06-25 |
2023-03-24 |
아뮤닉스 파마슈티컬스, 인크. |
Her-2 표적화 이중특이적 조성물 및 이의 제조 및 사용 방법
|
|
CA3192204A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
US11739144B2
(en)
|
2021-03-09 |
2023-08-29 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CLDN6
|
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
|
US20220332822A1
(en)
*
|
2021-04-16 |
2022-10-20 |
Tiziana Life Sciences Plc |
Subcutaneous administration of antibodies for the treatment of disease
|
|
JP2024520444A
(ja)
|
2021-05-24 |
2024-05-24 |
プロヴェンション・バイオ・インコーポレイテッド |
１型糖尿病を治療するための方法
|
|
EP4493592A1
(en)
|
2022-03-14 |
2025-01-22 |
LamKap Bio gamma AG |
Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
|
|
KR20250133776A
(ko)
|
2023-02-10 |
2025-09-08 |
아뮤닉스 파마슈티컬스, 인크. |
전립선-특이적 막 항원(psma)을 표적화하는 조성물 및 이의 제조 방법 및 사용 방법
|
|
CN121949565A
(zh)
|
2023-04-17 |
2026-05-01 |
阿穆尼克斯制药公司 |
靶向表皮生长因子受体的组合物及其制备和使用方法
|
|
KR20250019203A
(ko)
|
2023-07-31 |
2025-02-10 |
한국과학기술원 |
종양 침투 t세포의 종양 내 다클론성 증식을 통한 재조합 면역세포 기반 암 치료용 세포 치료제
|
|
WO2025193146A1
(en)
|
2024-03-13 |
2025-09-18 |
Berg Thoren Fredrik |
Trail receptor binding molecules
|
|
WO2025199352A2
(en)
|
2024-03-20 |
2025-09-25 |
Juno Therapeutics, Inc. |
Antibodies specific for solute carrier family 34 member 2 (slc34a2)
|
|
WO2025240670A2
(en)
|
2024-05-15 |
2025-11-20 |
Abalytics Oncology, Inc. |
Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
|
|
WO2026024863A2
(en)
|
2024-07-24 |
2026-01-29 |
Amunix Pharmaceuticals, Inc. |
Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists
|